Celcuity Raises $500M in Upsized Convertible Note Offering
Event summary
- Celcuity priced a $500M upsized offering of 0.250% convertible senior notes due 2032, up from $400M.
- Notes carry a conversion premium of ~40% above the last reported stock price of $124.53.
- Proceeds will repay $100M+ in outstanding debt to Oxford Finance and fund working capital, R&D, and potential acquisitions.
- Underwriters have a 30-day option to purchase an additional $75M in notes.
- Offering expected to close on June 8, 2026.
The big picture
Celcuity's $500M convertible note offering reflects the biotech sector's reliance on capital markets to fund late-stage clinical trials and potential commercialization. The upsized deal and conversion premium highlight investor confidence in the company's lead asset, gedatolisib, despite the high execution risk inherent in oncology drug development. The proceeds will provide financial runway as Celcuity navigates pivotal Phase 3 trials and potential regulatory milestones.
What we're watching
- Debt Repayment Impact
- How the repayment of $100M+ in outstanding debt will affect Celcuity's balance sheet flexibility.
- Conversion Premium Sustainability
- Whether the 40% conversion premium can be maintained as the company progresses through clinical trials.
- Acquisition Strategy
- The pace at which Celcuity may pursue acquisitions with the additional capital, given its focus on solid tumor therapies.
Related topics